Rosemont Deal Shows Value Is Out There For US Exit, Perrigo Says

Planned Separation ‘Will Take Some Time’

06 Aug 2020

Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.

Value — Perrigo will keep hold of its Rx business until a suitable multiple can be found for its sale • Source: Shutterstock

Perrigo Company PLC says the recent sale of its UK-based Rosemont Pharmaceuticals liquid generics business “proves” that attractive multiples are still out there in the generics space but it “will take some time” yet to complete the planned separation of its US Prescription Pharmaceuticals business, given the continued poor value Perrigo sees.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

17 Apr 2025

• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

Aurobindo Plots Rivaroxaban Roll-Out As FDA Approves 2.5mg Strength ANDA

17 Apr 2025

• By Dean Rudge

Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.

Tevogen Launches Generics-Focused Initiative As Trump Eyes Pharma Tariffs

16 Apr 2025

• By Adam Zamecnik

As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle